About Taste receptor type 2 member 60
Taste receptor type 2 member 60 (TAS2R60) is a protein
from Homo sapiens identified by UniProt accession
P59551, 318 residues long.
MolForge cross-references it against 0 known binders and
11 disease associations.
Target properties
| Protein name | Taste receptor type 2 member 60 |
| UniProt accession | P59551 |
| Gene | TAS2R60 |
| Organism | Homo sapiens |
| Length | 318 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (1)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (11)
Diseases linked to this target (Open Targets).
- glioblastoma multiforme · score 0.22
- lung adenocarcinoma · score 0.18
- breast adenocarcinoma · score 0.16
- squamous cell lung carcinoma · score 0.13
- head and neck squamous cell carcinoma · score 0.13
- gastric adenocarcinoma · score 0.10
- Alzheimer disease · score 0.09
- sex hormone-binding globulin measurement · score 0.09
- serum gamma-glutamyl transferase measurement · score 0.09
- calcium measurement · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P59551-F1 | alphafold | PREDICTED | 77.87 | — |
Amino-acid sequence (318 residues)
MNGDHMVLGS SVTDKKAIIL VTILLLLRLV AIAGNGFITA ALGVEWVLRR MLLPCDKLLV SLGASRFCLQ SVVMGKTIYV FLHPMAFPYN PVLQFLAFQW DFLNAATLWS STWLSVFYCV KIATFTHPVF FWLKHKLSGW LPWMLFSSVG LSSFTTILFF IGNHRMYQNY LRNHLQPWNV TGDSIRSYCE KFYLFPLKMI TWTMPTAVFF ICMILLITSL GRHRKKALLT TSGFREPSVQ AHIKALLALL SFAMLFISYF LSLVFSAAGI FPPLDFKFWV WESVIYLCAA VHPIILLFSN CRLRAVLKSR RSSRCGTP
Explore Taste receptor type 2 member 60 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets